Embed Size (px)
Citation preview
The changing healthcare landscape
ELRIG Drug Discovery keynote presentation
6 November 2019
Dr Melanie LeeCEO, LifeArc
Who is LifeArc? We're the charity helping turn promising science into benefits for patients
We have a 25-year legacy of collaborating with scientists on diagnostics and therapies, enhancing and protecting innovation and advancing promising research.
LifeArc is helping to bridge the gap from early research to patient benefit
Translation to de-risk and
advance towards the patient
The services we offer
4
Core Proposition Objectives What does this give our customers?
§ Deliver high-quality advice to academia and charities to enable them to translate early science into benefit for patients
§ A network of people / organisations that can help them turn their science into a market solution
§ Specialist expertise that they may not have in house
§ Access to LifeArc’s experience and knowledge from other projects§ The opportunity to develop their science at no upfront cost* and
without giving away their IP
§ Leverage LifeArc’s scientific expertise to bring projects too early for commercial operators through the stages of research and discovery, before partnering them out for commercialisation to patients
§ A collaborative partner providing experience and knowledge to advance their research
§ Specialist expertise / facilities that they may not have in house
§ The opportunity to develop their science at no upfront cost
§ Provide funding to support the development of innovative science, either philanthropically to drive reputation and impact, or with the aim of creating a sustainable return for LifeArc
§ The investment they need to progress their science – this can be in conjunction with receiving Translational advice or Translational science
§ A commercial partner who gives business coaching and maintains their focus on market viability
Translationalscience
Translational funding
Translational advice
*Excluding MRC SLA contract
Our funds are supporting UK translation
5
Philanthropic fund Seed fund VC fund
We are self-funded from revenues
CD / UC RA MS Cancer
• Raised $1.3bn from monetisation of royalty stream
• Investing in science to drive patient benefit
− Approved for 14 cancers to date as monotherapy or in combination:
− Harnessing the immune system is transforming our approach to cancer (and other diseases)
− Response rates can be >70%
− Hodgkins lymphoma - overall response rate of more than 70 percent, while 90 to 93 percent
of patients experienced a reduction in tumour size
− Advanced Melanoma Patients - overall response rate of 76% in combination with Dynavax’s
SD-101 (TLR9 agonist)
− 431 monotherapy and combination trials ongoing
Keytruda®
− Not every patient responds the same and some do not respond at all
− Some patients end up receiving Keytruda with no benefit
− Can the patients it will work for be predicted?
− It doesn’t work in every cancer
−Why not and can the cancers it will work for be predicted?
Keytruda® – some unanswered questions
The value gap
9
Pharma over-estimates market size from market research.
Payers consider generics and off-label use of existing drugs.
“Watch and wait” options considered
by payers.
Pharma builds in costs of attrition. Payers consider Pharma
already rewarded via tax credits.
Pharma over estimates patient impact. Payers unwilling to pay where patients don’t benefit.
The perspective on value is different between payers and industry.But payers now make the decisions on what to reimburse.
“Omics” - narrowing the value gap
10
Payers consider generics and off-label use of existing drugs.
“Watch and wait” options considered
by payers.
The perspective on value is different between payers and industry.But payers now make the decisions on what to reimburse.
“Omics” can help to identify real market
size. Patient stratification
“Omics” and AI can help reduce attrition.
Biomarkers and “Omics” direct treatment to only those that will benefit.
The current approach to treatment could be enhanced
Genomics will transform our ability to treat patients
We may be able to alter the course of disease development
DIAGNOSTICS DIGITAL
DEVICES DRUGS
Our vision: We will expediate change in translation to develop data-driven solutions that can
diagnose, prevent, monitor and treat disease.
− Profiling body’s immune response to detect natural response to cancer
− Enabling the earliest detection of cancer is key to timely initiation of treatment,
potentially saving lives and significantly reducing healthcare costs
− Revolutionising the detection and treatment of cancer
15
Changing landscape -
Changing landscape – Diabetes management
16Copyright: HealthLine
The changing healthcare landscape
ELRIG Drug Discovery keynote presentation
6 November 2019
Dr Melanie LeeCEO, LifeArc
